This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Don't Believe Osiris' Hype

One-year positive data released Tuesday by Osiris Therapeutics (OSIR - Get Report) from an ongoing study of its stem-cell treatment for knee repair should raise concerns about the results' reliability.

Surgical patients with osteoarthritis injected with the stem-cell therapy known as Chrondrogen experienced a statistically significant reduction in knee pain compared with control patients given an injection of hyaluronic acid, according to Osiris' analysis of one-year data from a phase II study.

But data from this same study were decidedly more negative when first disclosed last February. The disparity between Tuesday's results and those from 10 months ago is at least partly the result of changes made to the group of patients analyzed.

Osiris chose not to disclose Tuesday that the osteoarthritis patients who appear to have benefited from Chrondrogen make up just more than half of the 55 patients originally enrolled in this phase II study. The company also failed to mention that measurement of pain reduction was a secondary endpoint, not the primary endpoint, of the study.

That didn't stop Osiris shares from jumping more than 15% on Tuesday to $11.84.

Osiris' announcement also comes after the departure of its chief financial officer, which was disclosed the day after Thanksgiving.

Osiris is developing therapies derived from mesenchymal stem cells (MSCs), a form of adult stem cell capable of differentiating into tissues that provide rigidity or stability in the body -- bone, cartilage, fat, tendon or muscle. MSCs may also possess anti-inflammatory properties and appear not to activate an immune response when transplanted into an unrelated or unmatched host.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
OSIR $5.79 -1.40%
AAPL $93.56 -1.30%
FB $117.09 0.31%
GOOG $694.22 0.46%
TSLA $246.16 -0.63%


Chart of I:DJI
DOW 17,709.85 -120.91 -0.68%
S&P 500 2,064.99 -10.82 -0.52%
NASDAQ 4,777.2430 -28.0480 -0.58%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs